ASH 2024
Nicole Grieselhuber, MD, PhD on results of SEA-CD70 treatment in patients with high-risk MDS.
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Advertisement
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
Advertisement
Two experts discuss the role of surrogate end points in MPN clinical trials.
Dr. Patel discusses PFS and MRD negativity results from the CARTITUDE-4 trial of cilta-cel versus standard of care in MM.
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Dr. Callander discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.
The therapy under evaluation by two ongoing studies involves a new accelerated CAR T-cell product manufacturing process.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
There may be a link between obesity and how myeloproliferative neoplasms develop, research shows.
Rahul Banerjee, MD, of the Fred Hutchinson Cancer Center, discusses notable studies in myeloma presented at ASH 2024.
ASH recognized exemplary hematologist oncologists at the Announcement of Awards Ceremonies at the 66th Annual Meeting.
First-line, fixed-duration ibrutinib plus venetoclax provides durable PFS and OS for patients with CLL.
Venetoclax plus obinutuzumab demonstrates superior safety and efficacy compared with FCR and BR in untreated CLL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.